Reaction

Catheter Site Pain reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,508 reports · 83 co-occurring drugs

As of the last recalculation, Catheter Site Pain appears in 2,508 FAERS reports alongside 83 co-occurring drug terms. The strongest observed disproportionality signal is EPOPROSTENOL (PRR 250.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Epoprostenol	341	250.1	256.8
Macitentan	368	51.5	51.8
Treprostinil	554	46.7	46.9
Sildenafil	234	36.9	37.0
Sildenafil Powder,	139	34.3	34.4
Tadalafil	330	31.3	31.4
Riociguat	116	30.9	31.0
Sildenafil Citrate	358	27.1	27.1
Bosentan	151	26.4	26.5
Selexipag	73	24.1	24.2
0Xygen	122	21.6	21.6
Oxygen	122	21.6	21.6
Ambrisentan	251	18.4	18.5
Brinzolamide	19	18.3	18.3
Standardized Senna Concentrate	26	17.3	17.4
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	18	17.0	17.0
Bupivacaine	16	14.3	14.3
Sodium Chloride Tablet	118	13.9	13.9
Sodium Chloride Tablets	118	13.9	13.9
Adrenalinum	67	13.7	13.8
Sodium Chloride	122	13.4	13.4
Diphenhydramine Hydrochloride Capsule, Liquid Filled	31	12.2	12.2
Teduglutide	18	11.2	11.2
Amitriptyline Hydrochloride	23	11.0	11.0
Butalbital, Acetaminophen, And Caffeine	14	11.0	11.0
Agalsidase Beta	12	10.8	10.8
Ketoprofen	17	10.8	10.8
Buspirone Hydrochloride	14	10.6	10.6
Amantadine	19	10.3	10.3
Bumetanide	32	10.2	10.2
Warfarin	144	9.9	9.9
Pertuzumab	32	9.9	9.9
Epinephrine	72	9.4	9.4
Human Immunoglobulin G	22	8.9	8.9
Esomeprazole Magnesium Capsule, Delayed Release	15	8.6	8.6
Esomeprazole Magnesium Delayed Release Capsules	15	8.6	8.6
Esomeprazole Magnesium Dihydrate	15	8.6	8.6
Promethazine Hydrochloride	19	8.5	8.6
Doxyclycline Hyclate	17	8.3	8.3
Diphenhydramine	62	8.3	8.3
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	30	8.1	8.1
Eculizumab	52	8.1	8.1
Lidocaine Hydrochloride	55	7.7	7.7
Lidocaine	50	7.2	7.2
Lidicaine	40	6.9	6.9
Burn Relief	40	6.9	6.9
Lidocaine Hydrochloride And Epinephrine	40	6.9	6.9
Lidocaine, Menthol	40	6.8	6.8
Cyclobenzaprine	40	6.7	6.8
Spironolactone	106	6.5	6.5
Dextrose	10	6.3	6.3
Dextrose Monohydrate	10	6.2	6.2
Desloratadine	8	6.2	6.2
Lidocaine 4%	40	6.2	6.2
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	6	6.1	6.1
Fosaprepitant Dimeglumine	10	6.1	6.1
Daptomycin	6	5.4	5.4
Granisetron	6	4.8	4.8
Paricalcitol	8	4.7	4.7
Trastuzumab	38	4.6	4.7
Triamcinolone Acetonide Ointment Usp, 0.05%	13	4.6	4.6
Carbidopa And Levodopa	26	4.6	4.6
Aprepitant	10	4.5	4.5
Meropenem	17	4.4	4.4
Timolol	6	4.1	4.1
Rotigotine	7	4.0	4.0
Ado-Trastuzumab Emtansine	4	3.9	3.9
Doxorubicin Hydrochloride	15	3.8	3.8
Rasagiline Mesylate	5	3.7	3.7
Regorafenib	5	3.6	3.6
Prasugrel Hydrochloride	4	3.3	3.3
Mometasone Furoate And Formoterol Fumarate Dihydrate	6	3.2	3.2
Natalizumab	68	3.2	3.2
Abiraterone	5	3.1	3.1
Botulinum Toxin Type A	4	2.7	2.7
Pegfilgrastim	28	2.4	2.4
Trifluridine And Tipiracil	3	2.3	2.3
Apalutamide	3	2.1	2.1
Dornase Alfa	5	2.1	2.1
Elexacaftor, Tezacaftor, And Ivacaftor	3	2.0	2.0
Rimegepant Sulfate	3	2.0	2.0
Relugolix	5	1.8	1.8
Pimavanserin Tartrate	6	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.